JW (Cayman) Therapeutics Co Ltd
02126
Company Profile
Business description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact
No. 699 Zhong Ke Road
5th Floor, Building B
Pudong New District
Shanghai
CHNT: +86 2150464201
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
281
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors too optimistic about ASX growth story
Investors have gotten ahead of themselves with shares trading at a 94% premium to fair value.
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,103.10 | 47.20 | -0.52% |
| CAC 40 | 7,809.86 | 56.44 | 0.73% |
| DAX 40 | 24,223.50 | 198.72 | 0.83% |
| Dow JONES (US) | 44,843.70 | 385.09 | 0.87% |
| FTSE 100 | 9,159.92 | 12.11 | 0.13% |
| HKSE | 25,613.67 | 643.99 | 2.58% |
| NASDAQ | 21,791.92 | 110.01 | 0.51% |
| Nikkei 225 | 43,274.67 | 556.50 | 1.30% |
| NZX 50 Index | 12,766.54 | 6.86 | 0.05% |
| S&P 500 | 6,477.95 | 32.19 | 0.50% |
| S&P/ASX 200 | 8,827.10 | 53.70 | -0.60% |
| SSE Composite Index | 3,683.46 | 17.55 | 0.48% |